SG11201408262XA - Temperature stable vaccine formulations - Google Patents
Temperature stable vaccine formulationsInfo
- Publication number
- SG11201408262XA SG11201408262XA SG11201408262XA SG11201408262XA SG11201408262XA SG 11201408262X A SG11201408262X A SG 11201408262XA SG 11201408262X A SG11201408262X A SG 11201408262XA SG 11201408262X A SG11201408262X A SG 11201408262XA SG 11201408262X A SG11201408262X A SG 11201408262XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- maryland
- gaithersburg
- formulations
- pct
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 229960005486 vaccine Drugs 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 title abstract 4
- 241000193738 Bacillus anthracis Species 0.000 abstract 1
- 241000272168 Laridae Species 0.000 abstract 1
- 238000012356 Product development Methods 0.000 abstract 1
- 101710194807 Protective antigen Proteins 0.000 abstract 1
- 241000219995 Wisteria Species 0.000 abstract 1
- 208000022338 anthrax infection Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000005587 bubbling Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664062P | 2012-06-25 | 2012-06-25 | |
| US201361801385P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/047712 WO2014004578A1 (en) | 2012-06-25 | 2013-06-25 | Temperature stable vaccine formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408262XA true SG11201408262XA (en) | 2015-01-29 |
Family
ID=49783811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408262XA SG11201408262XA (en) | 2012-06-25 | 2013-06-25 | Temperature stable vaccine formulations |
Country Status (13)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015100344A1 (en) * | 2013-12-27 | 2015-07-02 | Emergent Product Development Gaithersburg Inc. | Temperature stable vaccine formulations |
| JP6741580B2 (ja) * | 2013-12-31 | 2020-08-19 | インフェクシャス ディズィーズ リサーチ インスティチュート | 単一バイアルのワクチン製剤 |
| US20170007694A1 (en) * | 2015-07-07 | 2017-01-12 | Nanobio Corporation | Methods and compositions for the stabilization of proteins |
| WO2017007835A1 (en) | 2015-07-07 | 2017-01-12 | Nanobio Corporation | Methods and compositions for nanoemulsion vaccine formulations |
| US20170007690A1 (en) * | 2015-07-07 | 2017-01-12 | Nanobio Corporation | Methods and compositions for the stabilization of anthrax recombinant protective antigen |
| CN109952372A (zh) | 2016-09-16 | 2019-06-28 | 白血球保健股份有限公司 | 获得有效用于疫苗接种或基因治疗的基于病毒载体的组合物的新方法 |
| US11510871B2 (en) | 2016-09-16 | 2022-11-29 | Leukocare Ag | Method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation |
| KR20190053908A (ko) | 2016-09-16 | 2019-05-20 | 로이코케어 아게 | 가공 동안 바이오 의약품의 안정화를 위한 신규한 방법 |
| KR101744900B1 (ko) | 2017-01-20 | 2017-06-08 | 주식회사 대웅 | 보툴리눔 독소를 포함하는 안정한 액상 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69530196T2 (de) * | 1994-06-02 | 2003-11-20 | Elan Drug Delivery Ltd | Methode zum verhindern der aggregation von proteinen/peptiden bei rehydratation oder auftauen |
| US7201912B2 (en) * | 2002-04-12 | 2007-04-10 | Emergent Biodefense Operation Lansing Inc. | Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis |
| US9283260B2 (en) * | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| CN100556400C (zh) * | 2006-07-20 | 2009-11-04 | 上海交通大学 | 载有活性疫苗或抗体的多糖玻璃体微粒的制备方法 |
| EP2068834A2 (en) * | 2006-09-08 | 2009-06-17 | Becton, Dickinson & Company | Stable powder formulations of aluma-dsorbed vaccines |
| AU2008231072B2 (en) * | 2007-03-22 | 2013-08-01 | The Regents Of The University Of Colorado | Method of preparing an immunologically-active adjuvant-bound dried vaccine composition |
| US8778359B2 (en) * | 2008-07-30 | 2014-07-15 | Emergent Biosolutions Inc. | Stable anthrax vaccine formulations |
| US20110212127A1 (en) * | 2008-09-24 | 2011-09-01 | Stabilitech Ltd. | Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine |
| AU2009338516A1 (en) * | 2009-01-22 | 2011-08-18 | Pharmathene, Inc. | Stable vaccine compositions and methods of use |
-
2013
- 2013-06-25 AU AU2013280480A patent/AU2013280480B2/en not_active Ceased
- 2013-06-25 IN IN38MUN2015 patent/IN2015MN00038A/en unknown
- 2013-06-25 US US14/410,942 patent/US20150335752A1/en not_active Abandoned
- 2013-06-25 JP JP2015520412A patent/JP2015525748A/ja not_active Withdrawn
- 2013-06-25 KR KR20157000755A patent/KR20150034170A/ko not_active Withdrawn
- 2013-06-25 RU RU2014151424A patent/RU2014151424A/ru not_active Application Discontinuation
- 2013-06-25 WO PCT/US2013/047712 patent/WO2014004578A1/en active Application Filing
- 2013-06-25 EP EP13809706.8A patent/EP2863898A4/en not_active Withdrawn
- 2013-06-25 SG SG11201408262XA patent/SG11201408262XA/en unknown
- 2013-06-25 CN CN201380037918.7A patent/CN104470506A/zh active Pending
- 2013-06-25 CA CA2877130A patent/CA2877130A1/en not_active Abandoned
- 2013-06-25 HK HK15108032.6A patent/HK1207312A1/xx unknown
-
2014
- 2014-12-21 IL IL236380A patent/IL236380A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014151424A (ru) | 2016-08-20 |
| IN2015MN00038A (enrdf_load_stackoverflow) | 2015-10-16 |
| IL236380A0 (en) | 2015-02-26 |
| HK1207312A1 (en) | 2016-01-29 |
| WO2014004578A1 (en) | 2014-01-03 |
| KR20150034170A (ko) | 2015-04-02 |
| AU2013280480A1 (en) | 2015-01-22 |
| US20150335752A1 (en) | 2015-11-26 |
| JP2015525748A (ja) | 2015-09-07 |
| CN104470506A (zh) | 2015-03-25 |
| CA2877130A1 (en) | 2014-01-03 |
| EP2863898A1 (en) | 2015-04-29 |
| AU2013280480B2 (en) | 2018-03-15 |
| EP2863898A4 (en) | 2016-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408262XA (en) | Temperature stable vaccine formulations | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201808552XA (en) | T-cell modulatory multimeric polypeptides and methods of use thereof | |
| SG11201903514VA (en) | Novel cd47 monoclonal antibodies and uses thereof | |
| SG11201906412SA (en) | Pyridine compounds as allosteric shp2 inhibitors | |
| SG11201807660QA (en) | Cyclic di-nucleotide compounds and methods of use | |
| SG11201804729RA (en) | Methods and compositions for treating a serpinc1-associated disorder | |
| SG11201408174UA (en) | Antibody formulation | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
| SG11201804443UA (en) | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201804647TA (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201810549TA (en) | Hiv vaccine formulation | |
| SG11201406987UA (en) | Glucokinase activator compositions for the treatment of diabetes | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201903893PA (en) | Synthetic chimeric poxviruses | |
| SG11201902988UA (en) | Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof |